Stepan, Daniel E.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 522

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 476

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine

Thyroid Cancer Diagnosis and TreatmentAngiogenesis and VEGF in Cancer

Cited by 470

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid Surgery

Cited by 340